

**REMARKS**

Applicants respectfully request that the foregoing amendments to Claims 1, 4-11, 13, 14, 17-21, 24-26, 28 and 29 be entered in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims.

Respectfully submitted,

Date December 12, 2001


FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5143  
Telephone: (202) 672-5427  
Facsimile: (202) 672-5399

By 

Bernhard D. Saxe  
Attorney for Applicant  
Registration No. 28,665

## VERSION WITH MARKINGS TO SHOW CHANGES

1. (Amended) A chemical compound of formula (I):



(I)

wherein:

R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen and alkyl;

R<sub>3</sub> is alkyl;

R<sub>4</sub> and R<sub>5</sub> are selected from hydrogen and alkyl;

R<sub>6</sub> and R<sub>7</sub> are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and

A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, [and] or pharmaceutically acceptable salt[s], addition compound[s] [and] or prodrug[s] thereof.

4. (Amended) A compound according to claim 1, [2 or 3] wherein R<sub>3</sub> is loweralkyl.

5. (Amended) A compound according to claim 1, [2 or 3] wherein R<sub>3</sub> is methyl.

6. (Amended) A compound according to [any preceding] claim 1 wherein R<sub>4</sub> and R<sub>5</sub> are independently selected from hydrogen and lower alkyl.

7. (Amended) A compound according to [any preceding] claim 1 wherein R<sub>6</sub> and R<sub>7</sub> are independently selected from hydrogen and lower alkyl.
8. (Amended) A compound according to [any of claims 1 to 5] claim 1, wherein one or more of R<sub>4</sub> to R<sub>7</sub> is/are hydrogen.
9. (Amended) A compound according to [any preceding] claim 1 wherein A is a 5- membered ring.
10. (Amended) A compound according to [any preceding] claim 1 wherein A is partially unsaturated.
11. (Amended) A compound according to [any preceding] claim 1 wherein A is a heterocyclic ring.
13. (Amended) A compound according to [any of claims 1 to 8] claim 1 wherein A is selected from the group consisting of cyclohexenyl, cyclopentenyl, phenyl, dihydrofuranyl, dihydropyranyl, dihydrothienyl, 2,3-dihydro-1,4-dioxin and tetrahydropyridinyl.
14. (Amended) A compound according to claim 1 wherein the compounds of formula (I) are selected from the group consisting of (S)-1-(benz[g]indolin-1-yl)-2-propylamine, (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine, (S)-1-(2,3,7,8-tetrahydrothieno[2,3-g]indol-1-yl)-2-propylamine, (S)-1-(2,3,7,8-tetrahydro-9H-pyrano[2,3-g]indol-1-yl)-2-propylamine, (S)-1-[1-(1,2,3,6,7,8-hexahydrocyclopent[g]indolyl)]-2-propylamine, [2S,3(R or S)]-1-(3-ethyl-2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine and [2S,3(S or R)]-1-(3-ethyl-2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine.
17. (Amended) A [use] method according to claim [16] 24, wherein the disorders of the central nervous system are selected from the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioural disorders, behavioural disorders

associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

18. (Amended) A [use] method according to claim [16] 24, wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases or toxic or infective CNS diseases.

19. (Amended) A [use] method according to claim 18, wherein said toxic or infective CNS disease is encephalitis or meningitis.

20. (Amended) A [use] method according to claim [16] 24, wherein the cardiovascular disorder is thrombosis.

21. (Amended) A [use] method according to claim [16] 24, wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.

24. (Amended) A method of treatment of [any of the disorders set out in claims 16 to 21] disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, comprising administering to a patient in need of such treatment an effective dose of a compound of formula (I) as set out in [any one of claims 1 to 14] claim 1.

26. (Amended) A method according to claim 24 [or 25], wherein said treatment is prophylactic treatment.

28. (Amended) A pharmaceutical composition comprising a compound of formula (I) as set out in [any one of claims 1 to 14] claim 1 in combination with a pharmaceutically acceptable carrier or excipient.

29. (Amended) A method of making a pharmaceutical composition, [according to claim 28] comprising combining a compound of formula (I) as set out in [any one of claims 1 to 14] claim 1 with a pharmaceutically acceptable carrier or excipient.